Regulatory approval
Published by the Health Canada. Approved
YERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Ipilimumab, Nivolumab, Pemetrexed |